E3 Breast Cancer Taxotere Combination

A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).

To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology

Inclusion Criteria:

• Females with histological/cytological confirmation of breast cancer.
• Subjects with a measurable lesion or bone lesions

Exclusion Criteria:

• Previous radiotherapy within 6 weeks
• Significant cardiac events, arrhythmias or other cardiac conditions